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S U M M A R Y
Background: Tuberculous meningitis (TBM) is the most severe form of tuberculosis. Microbiological
conﬁrmation is rare and treatment is often delayed. Early diagnosis and immediate initiation of
treatment are essential for effective TBM control. A systematic review was performed in this study to
assess the diagnostic accuracy of detecting antibodies against Mycobacterium tuberculosis in the
cerebrospinal ﬂuid (CSF), according to standard methods. Test performance was summarized using a
bivariate random-effects meta-analysis.
Methods: Studies were identiﬁed by a search of the literature, up to July 25, 2015, in the EMBASE and
MEDLINE databases via Ovid SP and PubMed. The Cochrane Library was also searched for original, peer-
reviewed molecular epidemiology studies that reported the diagnosis of TBM based on antibody
detection in the CSF.
Results: Thirty-six articles (58 studies) were identiﬁed. The sensitivity of antibody detection was 0.75
(95% conﬁdence interval (CI) 0.66–0.82), speciﬁcity was 0.98 (95% CI 0.96–0.99), and the area under the
receiver operating characteristic curve (AUROC) was 0.97 (95% CI 0.95–0.98). By subgroup analysis, the
detection of anti-M37Ra was the highest (AUROC 0.99, 95% CI 0.98–1.00), followed by anti-antigen 5
(AUROC 0.99, 95% CI 0.97–0.99) and anti-M37Rv (AUROC 0.97, 95% CI 0.95–0.98).
Conclusions: For the early diagnosis of TBM based on antibodies in the CSF, the detection of anti-M37Ra,
anti-antigen 5, or anti-M37Rv provides the greatest sensitivity and speciﬁcity.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Tuberculosis (TB) is a global public health priority, being the
single leading cause of death due to bacterial infection and the
second cause of death due to an infectious disease, accounting for
1.3 million deaths worldwide each year.1 By 2012, the prevalence
of active TB cases had fallen by 37% globally since 1990.2 However,
there are an estimated 8.6 million new cases of TB (range 8.3–9
million) globally per year, equivalent to an incidence of 122 cases
per 100 000 population.* Corresponding author. Tel.: +86 754 88900231.
E-mail address: yinge_wu@126.com (Y.E. Wu).
1 T.Y. Huang and X.X. Zhang contributed equally to this research and are co-ﬁrst
authors.
http://dx.doi.org/10.1016/j.ijid.2016.05.007
1201-9712/ 2016 The Author(s). Published by Elsevier Ltd on behalf of International S
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Tuberculous meningitis (TBM) is a severe complication of TB
that predominantly affects young children. Early treatment is vital
to prevent morbidity and mortality, emphasizing the importance
of early diagnosis. Bacteriological methods, such as Ziehl–Neelsen
staining and bacterial culture, remain the gold standard for the
laboratory diagnosis of TBM, because they identify the causative
agent of the disease, i.e. Mycobacterium tuberculosis, in cerebrospi-
nal ﬂuid (CSF). However, the acid-fast bacilli are seldom detected
in CSF smears, and culture methods are not only time-consuming,
but are also less sensitive. This lack of a sensitive method for early
diagnosis is the most common cause of delay, and has led to the
World Health Organization (WHO) recommending the Xpert MTB/
RIF assay (Cepheid, Inc., Sunnyvale, CA, USA) as the preferred initial
test for the diagnosis of TBM over conventional tests for the
diagnosis of TB in lymph nodes and other tissues.3 However, this
new technology is expensive, preventing its use in many of the
areas where the epidemic is most severe.4ociety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Figure 1. Flow chart of the selection of studies using antibody detection to diagnose
tuberculous meningitis.
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decades to devise a rapid test for M. tuberculosis based on antibody
detection. As a result of recent efforts to develop new tools for the
diagnosis of M. tuberculosis, several new diagnostics have been
introduced and evaluated.5–7 However, an accurate point-of-care
test that could be used within the peripheral clinical setting with
limited laboratory facilities has not yet been successfully devel-
oped.8 Systematic reviews have previously assessed the diagnostic
accuracy of adenosine deaminase (ADA) detection for M. tubercu-
losis in the CSF (10 studies).9 Depending on the classiﬁcation of
culture-negative clinical M. tuberculosis, pooled sensitivity esti-
mates range from 75% to 83%, and pooled speciﬁcity from 89% to
93%. However, focus has only been on the detection of ADA, and
neither of the previously published reviews appraised studies
involving antibody detection. The objective of the current
systematic review was to estimate the diagnostic accuracy of
antibody detection tests using CSF specimens for TBM in adults and
children with and without TBM infection.
2. Methods
A standard protocol for systematic reviews and meta-analyses
was followed,10 and methods recommended by the Cochrane
Diagnostic Test Accuracy Working Group were used.11
2.1. Data sources
Four databases were searched systematically for relevant
citations: EMBASE (January 1974 to August 2015) and MEDLINE
were searched via Ovid SP, PubMed (January 1946 to 25 July 2015),
and the Cochrane Library via the Wiley Online Library (Issue 12 of
25, July 2015). Databases were searched for original, peer-
reviewed molecular epidemiology studies that reported the
diagnosis of TBM based on antibody detection in the CSF. Keywords
were collected through expert opinion, literature review, con-
trolled vocabulary (medical subject headings (MeSH) and Excerpta
Medica tree (EMTREE)), and reviewing the results of test searches.
No language restrictions were imposed on the search criteria. The
search results were de-duplicated using EndNote X5.
2.2. Search strategy
The search strategy included a combination of the following
terms: ‘‘tuberculosis’’, ‘‘meningeal’’, and ‘‘diagnosis’’. The search
strategy is reported in full in the online Supplementary Material.
2.3. Eligibility criteria
Positivity by culture was used for TBM, as well as positivity in a
smear or on histopathological examination; positivity by com-
mercial NAA (1-naphthylacetic acid) tests was accepted because
these tests provide high speciﬁcity.12,13
2.4. Study selection
Initially, two reviewers (TYH and QLW) independently screened
the citations for relevance. Then, based upon pre-speciﬁed
selection criteria, these two reviewers independently reviewed
the full-text articles. Disagreements with regard to the study
selection were resolved by discussion between the reviewers.
2.5. Data analysis
Data were analyzed using Stata/IC 13.0 (StataCorp LP, College
Station, TX, USA). Forest plots were used to visually display
sensitivity and speciﬁcity estimates, and the 95% conﬁdenceintervals (95% CI) (using exact methods for proportions) from each
study were constructed using MetaDiSc 1.4 software (developed
by the Unit of Clinical Biostatistics team of the Ramo´n y Cajal
Hospital in Madrid Spain). Hierarchical summary receiver operat-
ing characteristic (HSROC) curves were analyzed to explore the
inﬂuence of threshold effects and to produce a global summary of
test accuracy. Heterogeneity of accuracy estimates was assessed
using the I2 test. Subgroup analyses were performed to study the
effects of different antibody detection tests. The area under the
receiver operating characteristic curve (AUROC) (with 95% CI) was
analyzed by Z-test in the subgroups.
2.6. Assessment of study quality
The QUADAS (Quality Assessment of Diagnostic Accuracy
Studies) criteria were used to assess the quality of diagnostic
accuracy in the studies.14 All studies were assessed against the
following four quality items: ﬂow and timing, reference standard,
index test, and patient selection. All criteria were classiﬁed as ‘high
risk’, ‘low risk’, or ‘unclear risk’ based on the information available
in the publication (see Supplementary Material Figure S1).
Studies were judged according to data used for the meta-analysis,
which may not have been all the data available in the publication.
This would apply if the study assessed the performance of the
antibody assay in M. tuberculosis suspects, as well as in healthy
controls. If possible, data from healthy controls were excluded for
the main analysis.
3. Results
The selection of the studies included in this review is summarized
in Figure 1. From the database search, 397 citations were identiﬁed.
Two hundred thirteen unique articles were left after excluding
duplicate articles. Following the screening of titles and abstracts,
98 potentially relevant articles were identiﬁed and these were then
retrieved for full-text review. Of these, 36 papers (58 studies,
5247 participants) were considered eligible for this study.15–50
3.1. Characteristics of studies included
The studies included were performed in India (n = 23),16–20,24–
26,30–37,39–42,46,47,50 South Africa (n = 1),15 China (n = 4),22,38,44,45
Kuwait (n = 1),27 Russia (n = 1),49 Thailand (n = 1),48 Colombia
(n = 1),23 Santiago (n = 1),43 the Philippines (n = 1),29 Korea
(n = 1),21 and the UK (n = 1).28CSF specimens were used for detection
Figure 3. Summary publication bias plots of the diagnostic odds ratio (DOR) and 1/
root of the effective sample size (ESS). Linear regression showed Egger p = 0.67,
indicating that publication bias was not found. Note: the ﬁgure in every dot
identiﬁes the number of the study (not the article).
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(13.8%) used other detection methods (one solid-phase radioimmu-
noassay, one passive hemagglutination assay, one radioassay, one
Western blot, four dot-immunobinding) (see Supplementary
Material Table S1). Antibodies against a single M. tuberculosis
antigen were detected in 23 (63.9%) of the articles, and antibodies
against multiple M. tuberculosis antigens were detected in 13 articles.
Among all of the studies, anti-M37Rv was the antibody most
frequently targeted (12 studies, 20.7%), followed by anti-antigen 5
(eight studies, 13.8%).
3.2. Accuracy estimates
Figure 2 shows a forest plot of the sensitivity and speciﬁcity
from individual studies. The meta-analytical average sensitivity
and speciﬁcity were 0.75 (95% CI 0.66–0.82) and 0.98 (95% CI 0.96–
0.99), respectively. Q-test Q-values were 599.34 and 532.64 (both
p < 0.05), I2 values were 90.49 and 89.30, and heterogeneity was
noted between studies. Meta regression analysis, to analyze the
heterogeneity, showed that the different kinds of antibody
detection methods were the source of the heterogeneity.
3.3. Publication bias
Funnel plots were drawn with the diagnostic odds ratio (DOR)
as the ordinate and 1/root of the effective sample size (ESS) as the
abscissa (Figure 3). Linear regression showed an Egger p-value of
0.67, indicating that there was no evidence of publication bias.Figure 2. Forest plots of the sensitivity and speciﬁcity of the antibody detection tests fo
between brackets. The ﬁgure shows the sensitivity and speciﬁcity estimates for individ3.4. SROC curve
The SROC curve was ﬁtted to show the ROC area. The AUROC
was 0.97 (95% CI 0.95–0.98). The positive likelihood ratio (PLR) and
negative likelihood ratio (NLR) were 36.6 (95% CI 20.5–65.5) andr tuberculous meningitis, all studies. The 95% conﬁdence intervals (CI) are included
ual studies (squares) and 95% CI (black horizontal lines).
Figure 4. Summary receiver operating characteristic plot of sensitivity and speciﬁcity
for the detection of antibody in the cerebrospinal ﬂuid for the diagnosis of tuberculous
meningitis. The square is the summary value for sensitivity and speciﬁcity. Note: the
ﬁgure in every dot marks the number of the study (not the article).
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the detection of M. tuberculosis antibody in the CSF could
accurately diagnose TBM (Figure 4). With the PLR as the ordinate
and NLR as the abscissa, a likelihood ratio scattergram was drawn.
There were eight studies (13.8%) that could both exclude and
conﬁrm M. tuberculosis (PLR >10, NLR <0.1).16,18,20,26,31,38,49,50
Twenty-nine studies (50.0%) could conﬁrm the diagnosis only (PLR
>10, NLR >0.1)19,21,22,24,26,27,29,30,32,34,37,39,41,44–47 (Figure 5).
3.5. Subgroup analyses and meta-regression
There was heterogeneity between the studies included in this
review. A meta-regression analysis was performed based onFigure 5. Likelihood ratio scattergram with positive likelihood ratio (PLR) and
negative likelihood ratio (NLR). Note: the ﬁgure in every dot marks the number of
the study (not the article). The articles that could exclude and conﬁrm
Mycobacterium tuberculosis (PLR >10, NLR <0.1) are those with reference
numbers 16, 18, 20, 26, 31, 38, 49, and 50. The articles that could conﬁrm the
diagnosis only (PLR >10, NLR >0.1) are those with reference numbers 19, 21, 22, 24,
26, 27, 29, 30, 32, 34, 37, 39, 41, 44, 45, 46, and 47.antibody targets, experimental methods, and the countries of the
studies, to analyze the heterogeneity (Supplementary Material
Table S2). The results showed that the different types of antibody
detection method were the source of heterogeneity, so subgroup
analyses of the different antibodies were performed. The
heterogeneity of sensitivity came from studies using anti-19 kD,
anti-38 kD, and anti-ESAT6. The heterogeneity of speciﬁcity came
from studies using anti-antigen 5, anti-PPD, anti-MTSE, anti-
M37Rv, anti-M37Ra, anti-LAM, and anti-A60 (Figure 6). Joint
model analysis revealed the heterogeneous sensitivity and
speciﬁcity came from anti-antigen 5, anti-19kd, anti-38kd, and
anti-ESAT6 (Supplementary Material Table S3).
For the subgroup meta-analysis, at least four studies were
required for inclusion in a subgroup. The number of studies on
anti-14 kD, anti-19 kD, and anti-ESAT6 was small (n < 4). There-
fore, these were not included in the meta-analysis. Subgroup SROC
curves showed AUC values for anti-M37Ra (0.99), anti-antigen 5
(0.99), anti-M37Rv (0.97), anti-PPD (0.94), anti-BCG (0.94), anti-
MTSE (0.93), anti-A60 (0.88), anti-LAM (0.80), and anti-38 kD
(0.55) (Table 1). The SROC curve AUC values indicated that the
detection of antibodies for antigen 5, M37Ra, M37Rv, PPD, BCG,
MTSE, A60, and LAM had the highest accuracy for the diagnosis of
TBM. In particular, the highest speciﬁcity was for the detection of
anti-M37Ra (0.99) in the CSF (Z-test, p < 0.01; see Supplementary
Material Table S4).
4. Discussion
High-quality systematic reviews, especially involving meta-
analyses, are considered to provide the most accurate evidence in
evidence-based medicine. Traditional bacteriological methods forFigure 6. Meta-regression analysis based on different antibody-directed antigens.
The sensitivity heterogeneity came from anti-19 kD, anti-38 kD, and anti-ESAT6.
The speciﬁcity heterogeneity came from anti-antigen 5, anti-PPD, anti-MTSE, anti-
M37Rv, anti-M37Ra, anti-LAM, and anti-A60.
Table 1
Pooled sensitivity, pooled speciﬁcity, and pooled likelihood ratios of the subgroups
Antibody No. of studies Pooled sensitivity Pooled speciﬁcity Pooled PLR Pooled NLR Pooled DOR Pooled SROC AUC
95% CI 95% CI 95% CI 95% CI 95% CI 95% CI
Anti-M37Ra 5 0.91 (0.71–0.98) 0.99 (0.89–1.00) 125.18 (7.8–2008.72) 0.09 (0.03–0.33) 1338.98 (115.34–15 543.92) 0.99 (0.98–1.00)
Anti-antigen 5 8 0.84 (0.71–0.92) 0.98 (0.96–0.99) 47.87 (18.6–123.4) 0.16 (0.08–0.32) 300.47 (71.68–1259.56) 0.99 (0.97–0.99)
Anti-A60 6 0.79 (0.67–0.88) 0.97 (0.72–1.00) 31.18 (2.36–411.64) 0.21 (0.13–0.34) 145.18 (12.50–1686.01) 0.88 (0.85–0.91)
Anti-LAM 4 0.67 (0.54–0.78) 0.99 (0.77–1.00) 45.53 (2.42–858.01) 0.33 (0.23–0.48) 136.05 (6.59–2807.39) 0.80 (0.76–0.83)
Anti-M37Rv 12 0.84 (0.71–0.92) 0.95 (0.91–0.98) 18.22 (8.58–38.70) 0.17 (0.09–0.32) 109.59 (30.21–397.50) 0.97 (0.95–0.98)
Anti-PPD 5 0.76 (0.66–0.84) 0.96 (0.91–0.99) 21.21 (7.55–59.63) 0.25 (0.17–0.37) 84.54 (22.62–316.00) 0.94 (0.91–0.95)
Anti-BCG 4 0.53 (0.31–0.73) 0.98 (0.93–0.99) 25.09 (6.35–99.05) 0.48 (0.30–0.79) 51.80 (9.67–277.49) 0.94 (0.91–0.95)
Anti-MTSE 4 0.85 (0.64–0.95) 0.91 (0.85–0.94) 0.98 (5.24–15.40) 0.16 (0.06–0.45) 55.20 (13.07–233.10) 0.93 (0.91–0.95)
Anti-38kd 4 0.25 (0.13–0.42) 0.99 (0.79–1.00) 25.86 (1.29–517.43) 0.76 (0.63–0.91) 34.17 (1.77–659.60) 0.55 (0.50–0.59)
PLR, positive likelihood ratio; NLR, negative likelihood ratio; DOR, diagnostic odds ratio; SROC, summary receiver operating characteristic; AUC, area under the curve; CI,
conﬁdence interval.
T.Y. Huang et al. / International Journal of Infectious Diseases 48 (2016) 64–6968clinical diagnosis need to be replaced gradually due to the length of
time required or because of low sensitivity. For diseases with high
morbidity and mortality, there is an urgent need for new, more
effective methods, such as serology. In the present study, 36 articles
(58 studies in total) evaluating antibody detection tests were
compared to identify rapid and accurate detection methods for the
early diagnosis of TBM. Through subgroup analysis, it was found
that the detection of anti-M37Ra had the highest pooled
sensitivity, PLR, DOR, and SROC AUC. The second highest was
the detection of anti-antigen 5, followed by the detection of anti-
M37Rv. Comparisons using the Student t-test showed that there
was little statistical difference in the results from the three
antibodies and that they were superior to the detection of the other
antibodies. This indicated that the detection of anti-M37Ra, anti-
antigen 5, or anti-M37Rv has the best likelihood of detecting TBM
and is more dependable for clinical application than the detection
of the other antibodies. Furthermore, testing for these three
antibodies in the CSF could also be used to diagnose patients with
symptoms suggestive of TBM.
The meta-analysis had some limitations restricting the
practicability of this study. First, although the 36 articles reviewed
here came from developing countries, including Asia, Europe, and
South America, the majority of publications originated in India
(23 papers, 63.9%). The other countries each accounted for 2.8%
(only one paper), except for China (four papers, 11.1%). Thus this
study does not entirely reﬂect the relevance of the application to
different races. Secondly, the retrieval of articles was not
sufﬁciently comprehensive because only the PubMed, EMBASE,
MEDLINE, and Cochrane Library databases were searched, and the
search objects were just for the studies that had been published,
which may leave out some other relevant studies, such as those
included in conference proceedings. Thirdly, most of the studies in
this review used ELISA to detect antibodies in the CSF, but six
studies used other methods (e.g. radioassay or Western blot). This
may have resulted in some discrepancy in the ﬁnal analysis.
In conclusion, this study conﬁrms that the detection of anti-
M37Ra, anti-antigen 5, and anti-M37Rv provides a superior
indication for TBM, with anti-M37Ra being the most practical.
The high sensitivity and speciﬁcity of these three antibodies
provide high practicability in the early screening for TBM and will
help the clinic in taking early measures to treat patients with
suspected TBM thus avoiding the serious consequences because of
delayed treatment.
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